MUNICH (Reuters) – Germany’s patent court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, a blow to CureVac’s claims for a share in billions in COVID-19 vaccine revenues.
(Reporting by Joern Poltz; Writing by Ludwig Burger, Editing by Rachel More)
